✦ LIBER ✦

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

✍ Scribed by Breccia, Massimo; Lo-Coco, Francesco

Book ID: 125475904
Publisher: Informa plc
Year: 2010
Tongue: English
Weight: 231 KB
Volume: 11
Category: Article
ISSN: 5847-4714
DOI: 10.1517/14712598.2011.543895

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and resistance of gemtuzumab oz

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia

✍ Akihiro Takeshita 📂 Article 📅 2013 🏛 Carden Jennings Publishing 🌐 English ⚖ 288 KB

Efficacy of gemtuzumab ozogamicin on ATR

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

✍ Takeshita, A; Shinjo, K; Naito, K; Matsui, H; Sahara, N; Shigeno, K; Horii, T; S 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 166 KB

Gemtuzumab ozogamicin in the treatment o

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

✍ Francis Giles; Elihu Estey; Susan O'Brien 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration

Final report of the efficacy and safety

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

✍ Richard A. Larson; Eric L. Sievers; Edward A. Stadtmauer; Bob Löwenberg; Elihu H 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 1 views

CD33-directed therapy with gemtuzumab oz

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

✍ Linenberger, M L 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB

Gemtuzumab Ozogamicin, A Potent and Sele

Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia

✍ Hamann, Philip R.; Hinman, Lois M.; Hollander, Irwin; Beyer, Carl F.; Lindh, Del 📂 Article 📅 2002 🏛 American Chemical Society 🌐 English ⚖ 147 KB